InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report released on Saturday morning. The firm issued a sell rating on the stock.

NSPR has been the subject of a number of other reports. Lake Street Capital initiated coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Down 1.9 %

InspireMD stock opened at $2.64 on Friday. The company’s 50 day moving average is $2.73 and its two-hundred day moving average is $2.70. The firm has a market cap of $68.86 million, a PE ratio of -3.52 and a beta of 0.98. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same period last year, the firm earned ($0.15) earnings per share. On average, equities research analysts anticipate that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.